Barinthus Biotherapeutics Plc. - ADR
BRNS
Get informed when a big investor buys or sells
+ FollowMarket Cap$27.81M
Close$
$1.46
121.2% upside
Current Fair Value
121.2% upsideUndervalued by 121.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $27.81 Million |
|---|---|
| Enterprise Value | $-26,726,159.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.64 |
| Beta | -0.6 |
| Outstanding Shares | 40,848,893 |
Return
| Return on Equity | -78.78% |
|---|---|
| Return on Assets | -56.77% |
| Return on Invested Capital | -33.75% |
Valuation & Multiples
| P/E Ratio | -0.53 |
|---|---|
| PEG | 0.74 |
| Price to Sales | - |
| Price to Book Ratio | 0.66 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.99 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.42 |
| Debt to Equity | 0.17 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 13, 2026
EPS Estimate
$-0.32
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-0.28
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Barinthus Biotherapeutics Plc.
109 employeesvaccitech is a spin-out company from the university of oxford’s jenner institute, one of the oldest and most renowned vaccine research centres in the world. the company has been formed around two viral vector vaccines, one to prevent inf...